MAPK3 and acute myeloid leukemia: Rao et al. demonstrated that alvespimycin treatment inhibited activated TRKA and its downstream signaling through p-AKT and p-ERK1/2, resulting in apoptosis of cell lines and primary human AML and CML cells [27].